Navigation Links
TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received
Date:12/16/2009

QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - TSO3 Inc. ("TSO3") (TSX: TOS) and 3M (MMM) today announced that an agreement has been reached for 3M to be the exclusive supplier and distributor of TSO3's STERIZONE(R) 125L+ Sterilizer. The partnership with TSO3, an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, will include new cycles to reach acute care facilities through 3M's global sales channel. This agreement, combined with recent improvements to the sterilizer performance in both cycle time and device compatibility, represents a significant step in the move to accelerate the product's adoption in the global marketplace.

"Our enhanced product offering, having three significantly faster and gentler cycles, makes the STERIZONE(R) Sterilization System an excellent alternative to shortcomings found in existing low temperature sterilization products. Our ability to sterilize a wide range of general surgical instruments, rigid channelled devices as well as simple and complex flexible endoscopes makes us unique and a single solution to what has historically required two or more sterilization technologies", Stated R.M. (Ric) Rumble, President and CEO of TSO3. "The agreement signed today with 3M pairs innovation in technology with innovation in marketing, sales and service on a global scale. It supports 3M's existing Infection Prevention business strategy, while significantly enhancing market penetration of the TSO3 technology. It is an excellent fit for our respective organizations and more importantly our mutual customers", Mr. Rumble continued.

While the details of the agreement are not being released, provisions include an exclusive license fee of which a portion is to be paid upfront, with milestone payments to be made linked to regulatory clearances, and, minimum purchases defined on an annual basis.

"We are very pleased to be able to offer this innovative technology to acute care settings for low temperature sterilization," stated Debra A. Rectenwald, Vice President and General Manager of the 3M Infection Prevention Division. "This technology is aligned with our 3M Infection Prevention goals to partner with hospitals to reduce hospital-acquired infections (HAIs) and to meet the needs of our customers and the patients they serve. The new agreement with TSO3 includes regional commercialization of the products as regulatory clearance or registration is obtained and we are enthusiastic to be able to offer this unique technology globally".

About 3M Infection Prevention Division

The 3M Infection Prevention Division offers healthcare professionals leadership solutions to minimize the risks of healthcare-associated infections. Combining science and technology, 3M Infection Prevention is built upon more than 40 distinct technology platforms and a comprehensive portfolio of quality products that help the healthcare industry define and address current infection prevention best practices. 3M Infection Prevention remains a trusted partner committed to helping customers lead the way in detecting, preventing and controlling the risk of infection. For more information, visit www.3M.com/infectionprevention.

About 3M

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With US $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries. For more information, visit www.3M.com.

About TSO3

TSO3, founded in Quebec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

In contrast to other methods, the ozone sterilization process developed and patented by TSO3 combines attributes that answer market needs for: efficacy, costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.

The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by the US and Canadian regulatory agencies for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearance from Health Canada and the United States regulatory agency for sterilization of additional complex medical devices, including multi-channel flexible endoscopes.

For more information about TSO3, visit the Company's Web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE TSO3 INC.


'/>"/>
SOURCE TSO3 INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
2. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
5. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Hospitals Agree to Pay Fees in Exchange for More Income, but Consumers in the Dark About What Theyll be Charged Under Nunez Plan
10. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
11. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology: